Characteristics of excluded studies

Supplementary material 3 to:
Fluvoxamine for the treatment of COVID-19

Nyirenda JLZ, Sofroniou M, Toews I, Mikolajewska A, Lehane C, Monsef I, Abu-taha A, Maun A, Stegemann M, Schmucker C
https://doi.org/10.1002/14651858.CD015391

Cochrane disclaims all liability and responsibility arising from any reliance placed on this supplementary material which has been supplied by the author(s). The above associated publication’s Author Licence will apply in respect of any supplemental materials published. How to cite the supplementary material is defined in the Cochrane policy.

Studies ordered by study ID

Study	Reason for exclusion
Assanovich 2021	Ineligible study design: a description of properties of fluvoxamine
Brown University 2021	Ineligible study design: not original study publication, rather a commentary on how fluvoxamine may limit deterioration from COVID-19
Glebov 2021	Ineligible study design: a highlight of protective effect of fluvoxamine antidepressant against COVID-19, highlighting therapeutic and prophylactic potential
Hashimoto 2021	Ineligible study design: a commentary on mechanisms of action of fluvoxamine for COVID-19
Khosravi 2022	Ineligible study design: a narrative review
Marcec 2021	Ineligible study design: description of fluvoxamine mechanisms of action and potential use in COVID-19 treatment
McCarthy 2021	Ineligible study design: paper reviewed the pleiotropic properties of fluvoxamine and explored how the drug may be used to treat the inflammatory sequelae of COVID-19 in the future
Medical Letter 2021	Ineligible study design: a commentary on properties of fluvoxamine
Murchu 2021	Ineligible study design: not an original publication
NCT04711863	Suspended Trial: trial was suspended due to closure of the main treatment centre
Seftel 2021	Ineligible study design: a prospective cohort study in real-world experience using fluvoxamine
Sukhatme 2021	Ineligible study design: description of fluvoxamine mechanisms of action and potential use in COVID-19 treatment

References to studies

Assanovich 2021 {published data only}

Assanovich M. Fluvoxamine in the treatment of patients with COVID-19. Psychiatry, Psychotherapy and Clinical Psychology 2021;12(2):260-8.

Brown University 2021 {published data only}

Anonymous. Study suggests fluvoxamine may limit deterioration from COVID‐19. Brown University Psychopharmacology Update 2021;32(4):6-7.

Glebov 2021 {published data only}

Glebov OO. Low-dose fluvoxamine modulates endocytic trafficking of SARS-CoV-2 spike protein: a potential mechanism for anti-COVID-19 protection by antidepressants. Frontiers in Pharmacology 2021;12:787261. [DOI: https://doi.org/10.3389/fphar.2021.787261]

Hashimoto 2021 {unpublished data only}

Hashimoto Y, Suzuki T, Hashimoto K. Old drug fluvoxamine, new hope for COVID-19. European archives of psychiatry and clinical neuroscience 2021;2:1-3. [DOI: https://doi.org/10.1007/s00406-021-01326-z]

Khosravi 2022 {published data only}

Khosravi M. Candidate Psychotropics against SARS - CoV-2: a narrative review. Pharmacopsychiatry 2022;55(1):16-23. [DOI: https://doi.org/10.1055/a-1551-3756]

Marcec 2021 {published data only}

Marcec R, Likic R. Could fluvoxamine keep COVID-19 patients out of hospitals and intensive care units? Croatian Medical Journal 2021;62(1):95-100.

McCarthy 2021 {published data only}

McCarthy MW. Repurposing approach of fluvoxamine for COVID-19. Drug Future 2021;46(10):813-8.

Medical Letter 2021 {published data only}

Anonymous. Fluvoxamine for COVID-19? Medical Letter on Drugs and Therapeutics 2021;63(1623):69-70.

Murchu 2021 {published data only}

Murchu EO, Spillane S, Byrne P, O'Neill M, Harrington P, Ryan M. Interventions in an ambulatory setting to prevent progression to severe disease in patients with COVID-19: a systematic review. Annals of Pharmacotherapy 2022;56(3):309-318. [DOI: https://doi.org/10.1177/10600280211028242]

NCT04711863 {unpublished data only}

NCT04711863. Fluvoxamine for adults with mild to moderate COVID-19 [Fluvoxamine for adults with mild to moderate COVID-19: a single-blind, randomized, placebo-controlled trial]. clinicaltrials.gov/ct2/show/record/NCT04711863 (first received 15 January 2021).

Seftel 2021 {published data only}

Seftel D, Boulware DR. Prospective cohort of fluvoxamine for early treatment of coronavirus disease 19. Open Forum Infectious Diseases 2021;8(2):ofab050.

Sukhatme 2021 {published data only}

Sukhatme VP, Reiersen AM, Vayttaden SJ, Sukhatme VV. Fluvoxamine: a review of its mechanism of action and its role in COVID-19. Frontiers in Pharmacology 2021;12:ofab050.

Supplementary material 3 to:Fluvoxamine for the treatment of COVID-19